RA Capital Management - Q4 2020 holdings

$7.15 Billion is the total value of RA Capital Management's 82 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 48.6% .

 Value Shares↓ Weighting
ASND SellASCENDIS PHARMA A Ssponsored adr$978,221,000
+7.3%
5,865,338
-0.8%
13.68%
-18.0%
TGTX SellTG THERAPEUTICS INC$451,818,000
+91.3%
8,685,471
-1.6%
6.32%
+46.2%
NVAX BuyNOVAVAX INC$422,463,000
+225.3%
3,788,564
+216.1%
5.91%
+148.7%
NKTX  NKARTA INC$344,547,000
+104.5%
5,605,1290.0%4.82%
+56.3%
FMTX  FORMA THERAPEUTICS HLDGS INC$314,507,000
-30.0%
9,011,6510.0%4.40%
-46.5%
ARVN  ARVINAS INC$311,937,000
+259.7%
3,672,8720.0%4.36%
+175.0%
CCXI SellCHEMOCENTRYX INC$295,764,000
+11.8%
4,776,548
-1.0%
4.13%
-14.6%
AVIR NewATEA PHARMACEUTICALS INC$224,294,0005,368,451
+100.0%
3.14%
ITOS  ITEOS THERAPEUTICS INC$149,392,000
+37.1%
4,417,2580.0%2.09%
+4.8%
KNTE NewKINNATE BIOPHARMA INC$142,932,0003,593,052
+100.0%
2.00%
AXSM SellAXSOME THERAPEUTICS INC$134,869,000
-7.0%
1,655,447
-18.7%
1.88%
-28.9%
KROS  KEROS THERAPEUTICS INC$132,263,000
+82.9%
1,875,0000.0%1.85%
+39.8%
PHAT  PHATHOM PHARMACEUTICALS INC$127,067,000
-9.4%
3,825,0080.0%1.78%
-30.8%
RYTM SellRHYTHM PHARMACEUTICALS INC$124,244,000
+11.5%
4,179,067
-18.7%
1.74%
-14.7%
TVTX NewTRAVERE THERAPEUTICS INC$124,225,0004,557,867
+100.0%
1.74%
IMGN BuyIMMUNOGEN INC$118,793,000
+368.7%
18,417,458
+161.6%
1.66%
+258.0%
RCKT NewROCKET PHARMACEUTICALS INC COM$117,143,0002,136,081
+100.0%
1.64%
ETNB  89BIO INC$115,422,000
-5.0%
4,736,2140.0%1.61%
-27.4%
ZGNX SellZOGENIX INC$106,859,000
+8.6%
5,345,631
-2.6%
1.49%
-17.0%
PMVP  PMV PHARMACEUTICALS INC$105,198,000
+73.3%
1,710,2650.0%1.47%
+32.4%
OLMA NewOLEMA PHARMACEUTICALS INC$103,391,0002,150,404
+100.0%
1.44%
ADVM BuyADVERUM BIOTECHNOLOGIES INC$103,006,000
+6.3%
9,502,383
+1.0%
1.44%
-18.8%
MGNX  MACROGENICS INC$100,017,000
-9.3%
4,375,2170.0%1.40%
-30.7%
PCVX SellVAXCYTE INC$98,593,000
-62.2%
3,710,699
-29.8%
1.38%
-71.1%
IGMS  IGM BIOSCIENCES INC$86,765,000
+19.6%
982,7230.0%1.21%
-8.6%
BDTX  BLACK DIAMOND THERAPEUTICS INC$83,006,000
+6.0%
2,589,9040.0%1.16%
-19.0%
SBTX NewSILVERBACK THERAPEUTICS INC$80,733,0001,742,186
+100.0%
1.13%
SellTRILLIUM THERAPEUTICS INC$77,823,000
-11.1%
5,290,481
-14.2%
1.09%
-32.1%
SLDB BuySOLID BIOSCIENCES INC$75,622,000
+715.0%
9,976,569
+118.3%
1.06%
+521.8%
KALA  KALA PHARMACEUTICALS INC$73,730,000
-9.6%
10,874,6130.0%1.03%
-30.9%
FPRX NewFIVE PRIME THERAPEUTICS INC$72,891,0004,285,161
+100.0%
1.02%
INBX  INHIBRX INC$70,193,000
+83.2%
2,129,0030.0%0.98%
+39.9%
LEGN  LEGEND BIOTECH CORPsponsored ads$67,818,000
-8.8%
2,408,2920.0%0.95%
-30.3%
CRIS NewCURIS INC$63,127,0007,707,790
+100.0%
0.88%
WVE  WAVE LIFE SCIENCES LTD$61,191,000
-7.3%
7,775,2070.0%0.86%
-29.2%
CRDF  CARDIFF ONCOLOGY INC$59,187,000
+26.8%
3,290,0000.0%0.83%
-3.2%
DYN  DYNE THERAPEUTICS INC$58,906,000
+4.0%
2,805,0450.0%0.82%
-20.6%
CNST NewCONSTELLATION PHARMCETICLS INC$53,359,0001,852,746
+100.0%
0.75%
PACB NewPACIFIC BIOSCIENCES OF CALIFORNIA INC$51,569,0001,987,997
+100.0%
0.72%
GERN  GERON CORP$47,901,000
-8.6%
30,126,2990.0%0.67%
-30.1%
STRO  SUTRO BIOPHARMA INC$45,986,000
+116.0%
2,118,2120.0%0.64%
+65.3%
CCCC NewC4 THERAPEUTICS INC$45,639,0001,377,569
+100.0%
0.64%
AKUS  AKOUOS INC$45,237,000
-13.3%
2,281,2490.0%0.63%
-33.8%
RLAY  RELAY THERAPEUTICS INC$41,560,000
-2.4%
1,000,0000.0%0.58%
-25.4%
INZY  INOZYME PHARMA INC$41,355,000
-21.5%
2,003,6530.0%0.58%
-40.0%
ORTX  ORCHARD THERAPEUTICS PLCads$41,155,000
-18.7%
12,315,2130.0%0.58%
-37.9%
ARDX SellARDELYX INC$39,875,000
+21.3%
6,163,086
-1.6%
0.56%
-7.3%
CERE NewCEREVEL THERAPEUTICS HLDNG INC$36,476,0002,200,000
+100.0%
0.51%
ARQT  ARCUTIS BIOTHERAPEUTICS INC$32,777,000
-4.0%
1,165,1840.0%0.46%
-26.6%
LRMR  LARIMAR THERAPEUTICS INC$32,439,000
+41.1%
1,515,1510.0%0.45%
+7.9%
VRNA  VERONA PHARMA PLCsponsored ads$31,824,0000.0%5,100,0000.0%0.44%
-23.5%
PAND  PANDION THERAPEUTICS INC$26,285,000
+29.6%
1,770,0230.0%0.37%
-1.1%
ALEC SellALECTOR INC$24,463,000
-35.8%
1,616,879
-55.3%
0.34%
-50.9%
CNCE SellCONCERT PHARMACEUTICALS INC$23,049,000
+26.3%
1,823,520
-1.9%
0.32%
-3.6%
SNDX  SYNDAX PHARMACEUTICALS INC$22,753,000
+50.7%
1,023,0670.0%0.32%
+15.2%
STSA  SATSUMA PHARMACEUTICALS INC$21,583,000
+18.5%
4,681,8580.0%0.30%
-9.3%
ORIC NewORIC PHARMACEUTICALS INC$19,768,000584,000
+100.0%
0.28%
SCPH  SCPHARMACEUTICALS INC$18,615,000
-29.0%
3,518,9980.0%0.26%
-45.8%
NewMARINUS PHARMACEUTICALS INC$15,860,0001,300,000
+100.0%
0.22%
VXRT SellVAXART INC$15,658,000
-78.2%
2,742,271
-74.6%
0.22%
-83.3%
MIST SellMILESTONE PHARMACEUTICALS INC$15,596,000
-11.9%
2,327,714
-3.8%
0.22%
-32.7%
OCUL SellOCULAR THERAPEUTIX INC$15,525,000
-25.2%
750,000
-72.5%
0.22%
-42.9%
BCTG  BCTG ACQUISITION CORP$14,300,000
+10.4%
1,250,0000.0%0.20%
-15.6%
RPTX  REPARE THERAPEUTICS INC$14,029,000
+11.5%
409,0000.0%0.20%
-14.8%
BLSA NewBCLS ACQUISITION CORP$13,925,0001,250,000
+100.0%
0.20%
ADAP SellADAPTIMMUNE THERAPEUTICS PLCsponds adr$13,470,000
-85.1%
2,499,025
-77.9%
0.19%
-88.6%
COGT NewCOGENT BIOSCIENCES INC$11,518,0001,025,641
+100.0%
0.16%
ARYA  ARYA SCIENCES ACQUISITION CO$10,850,000
+0.3%
1,000,0000.0%0.15%
-23.2%
FLACU NewFRAZIER LIFESCIENCES ACQUISITION COunit 12/09/2025$10,380,0001,000,000
+100.0%
0.14%
TXMD NewTHERAPEUTICSMD INC$9,453,0007,812,500
+100.0%
0.13%
LYRA  LYRA THERAPEUTICS INC$9,301,000
+0.5%
815,8490.0%0.13%
-23.1%
PASG  PASSAGE BIO INC$8,250,000
+95.0%
322,6300.0%0.12%
+49.4%
HSAQ  HEALTH SCIENCES ACQ CORP 2$8,006,000
+16.5%
625,0000.0%0.11%
-11.1%
HLXA NewHELIX ACQUISITION CORP$7,959,000700,000
+100.0%
0.11%
CRNX SellCRINETICS PHARMACEUTICALS INC$7,959,000
-78.2%
564,102
-75.8%
0.11%
-83.4%
FVAM New5 01 ACQUISITION CORP$7,628,000750,000
+100.0%
0.11%
MGEN NewMIRAGEN THERAPEUTICS INC$7,434,000451,932
+100.0%
0.10%
IMRA SellIMARA INC$5,486,000
+8.0%
248,804
-0.4%
0.08%
-17.2%
PROF NewPROFOUND MEDICAL CORP$3,954,000192,311
+100.0%
0.06%
XFOR SellX4 PHARMACEUTICALS INC$3,453,000
-8.8%
536,962
-4.0%
0.05%
-30.4%
CEREW NewCEREVEL THERAPEUTICS HLDNG INC*w exp 06/09/2027$1,318,000233,333
+100.0%
0.02%
OVID  OVID THERAPEUTICS INC$658,000
-59.8%
285,0000.0%0.01%
-70.0%
EPIX ExitESSA PHARMA INC$0-470,428
-100.0%
-0.06%
CLDX ExitCELLDEX THERAPEUTICS INC NEW$0-353,072
-100.0%
-0.10%
GRTX ExitGALERA THERAPEUTICS INC$0-825,118
-100.0%
-0.14%
ARYBU ExitARYA SCIENCES ACQUISITION CORPunit 06/09/2027$0-700,000
-100.0%
-0.14%
VSTM ExitVERASTEM INC$0-8,066,171
-100.0%
-0.18%
FSDC ExitFS DEV CORP$0-1,000,000
-100.0%
-0.20%
PRVL ExitPREVAIL THERAPEUTICS INC$0-1,915,568
-100.0%
-0.36%
RLMD ExitRELMADA THERAPEUTICS INC$0-781,290
-100.0%
-0.54%
RTRX ExitRETROPHIN INC$0-4,635,687
-100.0%
-1.56%
EIDX ExitEIDOS THERAPEUTICS INC$0-2,163,271
-100.0%
-2.00%
MCRB ExitSERES THERAPEUTICS INC$0-4,750,000
-100.0%
-2.46%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-02-16
Signatures

The EDGAR filing(s) were signed by:

About RA Capital Management

RA Capital Management is a Boston-based investment management firm that specializes in the healthcare sector. The firm was founded in 2001 by Peter Kolchinsky, a former biotech analyst at Lehman Brothers. Since then, RA Capital has grown to become one of the most respected healthcare investment firms in the world, with over $5 billion in assets under management.

The firm's investment strategy is focused on identifying and investing in companies that are developing innovative therapies and technologies that have the potential to transform the healthcare industry. RA Capital's team of experienced analysts and portfolio managers conduct extensive research and due diligence to identify the most promising investment opportunities in the healthcare sector.

RA Capital's portfolio includes a diverse range of companies, from early-stage startups to established biotech and pharmaceutical companies. Some of the notable companies in RA Capital's portfolio include Moderna, a biotech company that is developing a COVID-19 vaccine, and Intellia Therapeutics, a gene editing company that is developing therapies for genetic diseases.

Peter Kolchinsky, the founder and CEO of RA Capital, is a well-respected figure in the healthcare investment community. He is a frequent speaker at industry conferences and has authored several books on biotech investing. Other key members of RA Capital's management team include Rajeev Shah, the firm's COO, and Derek DiRocco, the Chief Investment Officer.

Overall, RA Capital Management is a highly respected investment firm that has a proven track record of identifying and investing in innovative healthcare companies. Investors who are interested in the healthcare sector may want to consider RA Capital as a potential investment opportunity.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ASCENDIS PHARMA A/S - ADR35Q3 202325.5%
WAVE LIFE SCIENCES PTE LTD32Q3 202326.3%
TG THERAPEUTICS INC30Q4 20216.3%
ZOGENIX INC26Q4 20219.5%
BIOCRYST PHARMACEUTICALS23Q1 20199.2%
DICERNA PHARMACEUTICALS INC23Q3 20195.8%
RHYTHM PHARMACEUTICALS INC22Q3 20234.4%
ACHILLION PHARMACEUTICALS INC19Q4 201717.2%
KALA PHARMACEUTICALS INC19Q1 20224.4%
SOLID BIOSCIENCES INC19Q3 20226.8%

View RA Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
RA Capital Management Q4 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
ARS Pharmaceuticals, Inc.September 25, 20239,459,6789.9%
CymaBay Therapeutics, Inc.September 22, 20236,940,0006.2%
BELLUS Health Inc.Sold outAugust 14, 202300.0%
Kinnate Biopharma Inc.Sold outAugust 14, 202300.0%
Vor Biopharma Inc.August 11, 202322,780,34333.7%
DICE Therapeutics, Inc.Sold outAugust 09, 202300.0%
Acumen Pharmaceuticals, Inc.July 25, 202314,981,61825.9%
Talaris Therapeutics, Inc.July 06, 20232,333,1755.5%
Aerovate Therapeutics, Inc.June 27, 20238,293,14830.0%
Satsuma Pharmaceuticals, Inc.Sold outJune 12, 202300.0%

View RA Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-28
32024-03-27
42024-03-27
32024-03-25
42024-03-25
SC 13G2024-03-25
SC 13G2024-03-25
SC 13D/A2024-03-18
SC 13D/A2024-03-11
42024-03-06

View RA Capital Management's complete filings history.

Compare quarters

Export RA Capital Management's holdings